BBOT

Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

Wall Street analysts forecast BBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBOT is 23.75 USD with a low forecast of 21.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BridgeBio Oncology Therapeutics Inc revenue for the last quarter amounts to -1.16M USD, increased 403.98 % YoY.

BridgeBio Oncology Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

BridgeBio Oncology Therapeutics Inc (BBOT) has 0 emplpoyees as of December 17 2025.

Today BBOT has the market capitalization of 947.87M USD.